Patent 1: “Complex matrix for biomedical use”
The invention concerns a complex matrix consisting of at least one cross-linked biocompatible biopolymer, which are grafted small chains of lower molecular weight (for example, hyaluronic acid), as well as a method for preparing such degradable biocompatible matrixes. Our ongoing research on “longer-lasting effects” is based on this patent.Patent 2: “Biocompatible cross-linked gel”
The invention relates to a method for producing a biocompatible cross-linked gel of hyaluronic acid. This method for producing such a gel allows Anteis to design new products with superior viscoelastic characteristics. The first technology which came out of this patented production method was CPM and Esthélis.Patent 3: “Biocompatible controlled-release gel,
its preparation process and its utilization”
This invention concerns a process for the preparation of a biocompatible gel with controlled release of one or more active lipophilic and/or amphilic ingredients. This patent suggests using cross-linked NaHa as a primary ingredient for the gel and a unique method of preparing a homogenous solution or suspension of pharmacological active ingredients with it. The nature of this gel allows slow release of the ingredient. We anticipate the use of this invention in our core business (aesthetic dermatology, ophthalmology and orthopaedics)as well as another therapeutic field, in collaboration with the pharmaceutical industry.
Patent 4: “Viscoelastic gel for dermatological use”
The invention concerns a natural dermatological polysaccharide gel comprising a polysaccharide aqueous solution (for example, a hyaluronic acid) and a biocompatible viscous highly hydrophilic alcohol (for example, a glycerol) and possibly, adjuvants used in dermatology. The association of HA and glycerol provides superior hydratation capabilities compared to regular formulations. Mesolis+ was the first development to take advantage of this patent.
recommendprint this page top
